Placing on the market planned in Turkey

Lyon, 1st July 2019 – AMOÉBA announces that Willaertia magna C2c Maky effectively treats rust, a group of diseases that decimates field crops, such as soybean and wheat. The study, undertaken by an independent expert, demonstrated more than 85% efficacy when lysed W. magna was applied according to a standard protocol. Following on from the excellent results obtained with W. magna used as a treatment for downy mildew of grapevine and late blight of potato, its action on Uromyces fabae fungi confirms that the amoeba is a potential biocontrol agent with a broad spectrum of action.

Chassieu, 7 March 2019 – Two scientific studies involving the biocontrol product produced by AMOEBA demonstrate that it protects grapevines from downy mildew (Plasmopara viticola)through two additive actions.Used in its lysed form, Willaertia magna C2c makyboth stimulates the grapevines’ natural defences and directly attacks the fungus feared by wine growers.AMOEBA is not currently aware of any other commercially-available biocontrol agent based on a natural substance that elicits a response from the grapevines themselves while also inhibiting germination of downy mildew.“This product represents an alternative that could significantly reduce the use of conventional pesticides, while also protecting wine growers’ yields.”comments Fabrice Plasson, President of AMOEBA.

Lyon, 4th Mai 2018 - AMOEBA announces today the first greenhouse test results conducted with the microorganism, Willaertia magna C2c Maky, used as a biocontrol agent for the control of mildew on grapevine.

 The results of the first greenhouse trials show very clear dose-responses of Willaertia magna C2c Maky in a formulated product. The efficacy of more than 90% of the formulated product on mildew has to be compared to the usual efficacy of biocontrol agents of around 50% observed in greenhouses. A new series of tests is scheduled in 2018 in preparation of the field trials planned in 2019. 

Lyon, November 22^nd, 2017- AMOEBA announced today the positive results of in vitro trials conducted with Willaertia Magna C2c Maky microorganism for the control of plant diseases.

Those in vitro trials were carried out by the company CONIDIA, recognized for its broad expertise in fungi and their resistance to fungicides.

Lyon (France), Lancy (Switzerland), November 8^th, 2017 - AMOEBA announced today that it has signed a Letter of Intent (LOI) with H2O FACILITIES prior to entering into a definitive agreement regarding the distribution of its product in Switzerland, pending marketing authorization.

Lyon, October 9^th, 2017 - Amoéba has received financing worth EUR 20m from the EIB. This EIB financing is secured by the European Fund for Strategic Investments (EFSI), the cornerstone of the Investment Plan for Europe, commonly known as the Juncker Plan.

Lyon (France), Rome, September 14^th, 2017 - AMOEBA announced today that it has signed a distribution agreement for its BIOMEBA product with DREWO. This agreement is pending marketing authorization (MA) in Italy.

The collaboration between DREWO and AMOEBA started in November 2015 with the signature of a Letter of Intention (LOI). In August 2016, both companies carried out a first field test in Italy for an industrial company in the automotive sector. This test, still ongoing today, has confirmed the effectiveness of BIOMEBA. Following this success, this car manufacturer wishes to start a new field test on another industrial site before the end of the year. Meanwhile, a second test has started in January 2017 with a client of DREWO from the food industry.

Lyon, Friday 25th August 2017 – For the 3rd consecutive year Amoéba will participate at the annual exhibition of industrial water treatment specialists in the United States organized by AWT, Association of Water Technologies. During this event, Amoéba will present its biological biocide BIOMEBA to US water treater.

Lyon (France), Atlanta (GA, USA), July 27th, 2017 – Amoéba announced today that it has signed a Letter of Intent (LOI) with MOMAR Inc. prior to entering into a definitive agreement regarding the distribution of its product in the United States pending marketing authorization. The signature of this agreement allows AMOEBA to extend its commercial cover for the distribution of the green biocide BIOMEBA on the South-East states of the United States including mainly agri-food and aerospace industries.

Fabrice Plasson, CEO of Amoéba, was elected at the new board of the WssTP’s, for the period 2017-2019. He’ll be representing College D: Suppliers & SME’s.  The election took place during the WssTP Annual general meeting held during the Water Innovation Europe 2017 conference on 14th June 2017.